ArticleBMC nephrology2026
FSTIV score is essential for clinical management and predicts outcome of idiopathic membranous nephropathy.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundsThe FSTIV score, an acronym derived from Focal, Segmental, Tubular, Interstitial, and Vascular, is a histopathological scoring system based on light microscopy that incorporates four parameters: focal segmental glomerulosclerosis (FSGS), tubular atrophy (TA), interstitial fibrosis (IF), and vascular hyalinosis (VH). This study aimed to investigate the associations among the FSTIV score, clinicopathological characteristics, and initial treatment response in patients with idiopathic membranous nephropathy (IMN).
methodsWe retrospectively enrolled 139 patients with biopsy-proven IMN from a single center between June 2019 and September 2023. The FSTIV score was calculated using four histological parameters (FSGS, TA, IF, and VH). Patients were categorized into four groups according to their FSTIV scores. Logistic regression analysis was performed to identify risk factors for elevated FSTIV score. The impact of histology on treatment response within 6 months after renal biopsy was evaluated.
resultsHigher FSTIV scores were associated with older age, a greater prevalence of hypertension and nephrotic syndrome, and worse renal function. Across increasing FSTIV categories, the prevalence of each individual component (FSGS, TA, IF, and VH) showed a stepwise increase.Logistic regression analysis identified hypertension (OR = 2.460, 95%CI: 1.202–5.208) and 24-hour proteinuria (OR = 1.0001, 95%CI: 1.0000-1.0002) as independent predictors of higher FSTIV scores. The remission rates within 6 months after renal biopsy decreased significantly with increasing FSTIV scores (87.5%, 61.8%, 39.0% vs. 76.4%; P < 0.001), indicating a diminished response to immunosuppressive therapy.
conclusionsHigher FSTIV scores were associated with more severe clinical and pathological presentations in IMN patients. Hypertension and 24-hour proteinuria were independent risk factors for an increased FSTIV score, which correlated with a poorer response to treatment and lower remission rates. The FSTIV score serves as a valuable tool for assessing disease severity, guiding treatment decisions, and predicting renal outcomes in patients with IMN. CLINICAL TRIAL: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.